NSE: ATUL | BSE: 500027

Mid-range Performer

Download real time

6841.00 54.00 (0.80%)

43.96% Gain from 52W Low

57,574 NSE+BSE Volume

NSE 19 May, 2025 3:31 PM (IST)

20,141.1

Market Cap

High in industry

1.0

Beta 1Year

Average volatility

Atul Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for ATUL, BSE:500027 Atul Ltd.

Search Inside the pdf :

Atul Ltd.

06 May 2025

6841.00

0.80%

Capacity in action: Utilization gains to drive earnings; Buy

Buy: Atul Ltd.

Anand Rathi

Atul invested ~Rs20bn over the last three years in setting up capacity (capex matching the cumulative investment over the last decade). In its analyst meet, management highlighted unrealized sales potential of over Rs25bn from recently concluded capex (~Rs17bn) and from previously unutilized capacity (~Rs8bn).

Anand Rathi released a Buy report for Atul Ltd. with a price target of 8300.0 on 06 May, 2025.

Atul Ltd.

03 May 2025

6841.00

0.80%

Stellar bounce-back in FY25; growth expected to continue

Buy: Atul Ltd.

Target

Motilal Oswal

Atul’s (ATLP) 4QFY25 revenue came in line with our expectation. The Life Science Chemicals (LSC) segment’s revenue increased 18% YoY, while the Performance & Other Chemicals (P&OC) segment’s revenue rose 21% YoY.

Atul Ltd. has gained 20.42% in the last 1 Month

Atul Ltd.

23 Apr 2025

6841.00

0.80%

Ripe for volume growth; cheap valuation, favorable risk-reward

Buy: Atul Ltd.

Emkay

We initiate coverage on Atul with BUY and TP of Rs8,500 (30x Mar-27E EPS). Atul has invested ~Rs20bn over FY22-24 toward capacity expansion in existing products like Liquid Epoxy Resin (50ktpa) and Caustic Soda (300tpd), and in the backward integration of some key products (MCA for 2,4 D).

Atul Ltd. has gained 20.42% in the last 1 Month

Atul Ltd.

26 Jan 2025

6841.00

0.80%

The Life Science segment continues its stellar performance

Buy: Atul Ltd.

Target

Motilal Oswal

Atul (ATLP) reported revenue 7% above our expectation in 3QFY25. Revenue in the Life Science Chemicals segment increased 23% YoY, while it rose 24% YoY in the Performance & Other Chemicals segment

Atul Ltd. has an average target of 8611.60 from 5 brokers.

Atul Ltd.

13 Nov 2024

6841.00

0.80%

Signs of recovery evident in financial performance

Buy: Atul Ltd.

Target

Sharekhan

Topline rose 17% y-o-y and 5% q-o-q, with operating Profit of Rs. 243 crore and adjusted
PAT of Rs. 112 Crore surpassing our estimates, attributed to margin enhancements in
LSC and POC.

Atul Ltd. is trading below its 200 day SMA of 6940.6

Atul Ltd.

27 Oct 2024

6841.00

0.80%

Impressive show continues in both the business segments

Buy: Atul Ltd.

Target

Motilal Oswal

Atul (ATLP) reported in-line revenue in 2QFY25. Revenue in the Life Science Chemicals segment increased 13% YoY, while it rose 18% YoY in the Performance & Other Chemicals segment.

Number of FII/FPI investors decreased from 204 to 186 in Mar 2025 qtr

Atul Ltd.

31 Jul 2024

6841.00

0.80%

Atul Ltd

Buy: Atul Ltd.

Target

CD Equisearch

Atul Ltd. has an average target of 8611.60 from 5 brokers.

Atul Ltd.

27 Jul 2024

6841.00

0.80%

Rising like a Phoenix!

Buy: Atul Ltd.

Recommendation Target

Motilal Oswal

ATLP has burned for three long years (FY22-24) and it is a classic case of valuations perched higher despite a significant decline in earnings. During FY22/FY23/ FY24, EBITDA declined 1%/15%/18% YoY .

Number of FII/FPI investors decreased from 204 to 186 in Mar 2025 qtr

Atul Ltd.

19 Jul 2024, 12:00AM

6841.00

0.80%

Signs of Recovery Evident in Financial Performance

Buy: Atul Ltd.

Recommendation Target

Sharekhan

Consolidated revenue for Q1FY2025 was Rs. 1,322 crore, reflecting a 12% increase from the previous year and a 9% rise from the previous quarter, slightly exceeding our estimate of Rs. 1,314 crore by 1%.

Atul Ltd. has gained 20.42% in the last 1 Month

Atul Ltd.

02 May 2024

6841.00

0.80%

Pricing pressure continues to hurt performance

Neutral: Atul Ltd.

Target

Motilal Oswal

Atul (ATLP) reported in-line revenue in 4QFY24. Revenue in the Life
Science Chemicals segment declined 8% YoY, while it increased 5% YoY in
the Performance & Other Chemicals segment.

Atul Ltd. has gained 26.80% in the last 3 Months

Is Atul Ltd. worth buying?

178 Votes:

Buy 75.28%

Sell 14.04%

Hold 10.67%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf